Discontinuation report ERWINASE

Last updated on 2021-03-31 History
Report ID 129623
Drug Identification Number 02237815
Brand name ERWINASE
Common or Proper name Erwinia L-asparaginase
Company Name JAZZ PHARMACEUTICALS FRANCE SAS
Market Status MARKETED
Active Ingredient(s) ASPARAGINASE
Strength(s) 10000UNIT
Dosage form(s) POWDER FOR SOLUTION
Route of administration INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS
Packaging size 3 mL vials
ATC code L01XX
ATC description OTHER ANTINEOPLASTIC AGENTS
Reason for discontinuation Business reasons
Anticipated discontinuation date 2021-04-01
Actual discontinuation date
Remaining supply date 2021-02-28
Discontinuation status To be discontinued
Discontinuation decision reversal No
Information on remaining supply Lot 205H121 is out of stock. Supply of lot 205H121 has been prioritized for existing patients.
Company comments Distribution of Erwinase by Jazz Pharmaceuticals will end now that lot 205H121 (“CAMR205”) is exhausted. For all enquiries about future supply beyond Lot 205H121, please contact Clinigen at https://www.clinigengroup.com/direct/en-gb/products/detail/erwinia-l-asparaginase
Health Canada comments
Contact Address 84 QUAI CHARLES DE GAULLE CITY ONE
LYON, AUVERGNE-RHONE-ALPES
FRANCE 69006
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v9 2021-03-31 French Compare
v8 2021-03-31 English Compare
v7 2021-03-31 English Compare
v6 2021-03-31 English Compare
v5 2020-12-11 French Compare
v4 2020-12-11 English Compare
v3 2020-12-04 French Compare
v2 2020-12-04 English Compare
v1 2020-12-04 English Compare